Pulmonary fibrosis is a pathological condition that is classically characterised
by excessive and disorganised deposition of extracellular matrix (ECM) within the pulmonary interstitium. The main areas affected include the alveolar walls (including the epithelium and capillary endothelium), septae and the perivascular, perilymphatic and peribronchiolar connective tissue.
It is generally held that this condition occurs as an aberrant wound healing response to acute or chronic lung injury. It profoundly compromises alveolar gas exchange and hence often leads to premature death. Varying degrees of pulmonary fibrosis in conjunction with inflammation are the hallmark of all Interstitial lung diseases (ILDs), which are a heterogeneous group of over 200 different disorders.
In the current study lung fibrosis characters were reduced by only Absogen,
Abronym, Zerilox and their combinations, but not by the GC and Vindia and their combinations. A remarkably interesting observation was made that not only GC and Vindia did not show the effect but also, they inhibited the effect exerted by Absogen, Abronym and Zerilox when mixed. It shows the cell and disease specific effect of used drugs.
Absogen, Abronym and Zerilox showed the reduction in fibrotic properties in an individual manner as well as in combinations. When the drugs were treated with individual drugs the increasing order was found for Absogen, Abronym and Zerilox, means Zerilox showed the highest effect when mixed with the cells alone (Maximum value around 34% on day 14). The effect for all 3 was there in a dose dependent and concentration dependent manner. In the case of lung fibrosis characters, the reduction effect was more of acute type where only after the 3-day incubation the combination of Absogen, Abronym and Zerilox showed reduction of nearly 30 percent on day 3 itself which increased to 57 percent on day 7 and then got stabilized on 59 percent on day 14.